Delving into the Latest Updates on Shanghai Xinshengyuan Biological Medicine Co. Ltd. with Synapse

Overview

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Other Diseases

Growth factors

Fusion protein

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Growth factors	1
Fusion protein	1

Top 5 Target	Count

FGFR2(Fibroblast growth factor receptor 2)	1
MUC1(Mucin-1)	1

The engineered NS0 myeloma cell line was used to express recombinant anti-human CD25 chimeric monoclonal antibody.The cell cultivation and expression process was investigated in a 5 L cell reactor.The average yield of target product in cell suspensions was 108 mg/L, and about 4 L cell suspensions were harvested from each batch.The target product with purity over 95% and recovery rate around 33% was purified from harvested supernatant by a two-step purification process using rProtein A Sepharose FF and SP Sepharose FF chromatog.Western blotting proved that the expressed and purified protein was identical to the target product and retained the immunogenicity of the target product.Anal. result showed that fifteen amino acid residues of the N-terminal were identical to the theor. sequence.

100 Deals associated with Shanghai Xinshengyuan Biological Medicine Co. Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Xinshengyuan Biological Medicine Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 13 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Phase 3 Clinical

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant human keratinocyte growth factor-2(Shanghai Newsummit Biopharma) ( FGFR2 )	Burns More	Phase 3
Recombinant HSP-MUC1 fusion protein(Shanghai Xinshengyuan Biological Medicine Co. Ltd.) ( MUC1 )	Breast Cancer More	Phase 1
Recombinant SuperCompound Interferon(Shanghai Xinshengyuan Biological Medicine Co. Ltd.) ( IFNAR )	Virus Diseases More	Discontinued
Isatin ( MAO-B )	Parkinson Disease More	Pending
IL-2(Shanghai Xinshengyuan Biological Medicine Co. Ltd.) ( IL-2R )	Gastrointestinal Neoplasms More	Pending